Header Logo

Connection

Ricardo Perez to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications Ricardo Perez has written about Carcinoma, Non-Small-Cell Lung.
Ricardo Perez
Connection Strength
0.452
Carcinoma, Non-Small-Cell Lung
  1. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.
    View in: PubMed
    Score: 0.167
  2. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
    View in: PubMed
    Score: 0.156
  3. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.
    View in: PubMed
    Score: 0.129
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.